MarketCap
Facebook
X
Telegram
Tyme Technologies EBITDA | TYME
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Tyme Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.5 M | -27.2 M | -25.8 M | -31.8 M | -8.07 M | -5.56 M | -2.99 M | -2.43 M | -2.58 M | -56.6 K | -27.4 K | -2.1 K |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.1 K | -31.8 M | -11 M |
Quarterly EBITDA Tyme Technologies
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.61 M | - | -5.88 M | -5.93 M | -6.65 M | -5.89 M | -5.87 M | -7.32 M | -7.77 M | -5.87 M | -6.54 M | -6.24 M | -6.18 M | -6.54 M | -8.07 M | -7.01 M | -6.72 M | -8.08 M | -8.07 M | -7.01 M | -5.31 M | -5.56 M | -5.56 M | -5.29 M | -3.19 M | -2.99 M | -3.12 M | -5.87 M | -2.89 M | -2.44 M | -2.31 M | -1.75 M | -2.1 M | - | -885 K | -144 K | -127 K | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -127 K | -8.08 M | -5.08 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Puma Biotechnology
PBYI
|
48.2 M | $ 10.85 | -1.54 % | $ 543 M |  USA |
 |
Processa Pharmaceuticals
PCSA
|
-14 M | $ 1.76 | -2.76 % | $ 2.3 M | USA |
 |
Vaxcyte
PCVX
|
-907 M | $ 59.95 | -0.79 % | $ 8.16 B | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-172 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
16.3 M | - | - | $ 8.14 B | USA |
 |
Pfizer
PFE
|
6.59 B | $ 29.8 | -0.78 % | $ 169 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
1.01 B | - | - | $ 26.6 B |  Irlanda |
 |
Pharming Group N.V.
PHAR
|
74 M | $ 11.85 | 5.8 % | $ 8.16 B |  Niderland |
 |
Phathom Pharmaceuticals
PHAT
|
-159 M | $ 5.94 | 3.48 % | $ 433 M | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
-9.22 M | $ 0.87 | 2.04 % | $ 5.21 M | USA |
 |
Lantern Pharma
LTRN
|
-18 M | $ 0.6 | -5.34 % | $ 6.54 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-45.7 M | - | - | $ 121 M | USA |
 |
Pliant Therapeutics
PLRX
|
-155 M | $ 0.85 | -1.64 % | $ 52.2 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-30.3 M | - | -33.41 % | $ 3.37 M | USA |
 |
Praxis Precision Medicines
PRAX
|
-326 M | $ 267.68 | 5.82 % | $ 6.02 B | USA |
 |
PainReform Ltd.
PRFX
|
-5.11 M | $ 0.74 | 0.07 % | $ 480 K |  Israel |
 |
Prelude Therapeutics Incorporated
PRLD
|
-103 M | $ 3.69 | 1.65 % | $ 284 M | USA |
 |
iTeos Therapeutics
ITOS
|
-158 M | - | - | $ 411 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-43.4 M | $ 1.23 | -4.65 % | $ 130 M | Niderland |
 |
Prothena Corporation plc
PRTA
|
-214 M | $ 8.38 | 2.2 % | $ 451 M | USA |
 |
PTC Therapeutics
PTCT
|
906 M | $ 61.04 | 0.74 % | $ 4.85 B | USA |
 |
Protagonist Therapeutics
PTGX
|
-157 M | $ 140.24 | 1.31 % | $ 8.92 B | USA |
 |
Pulmatrix
PULM
|
-1.29 M | $ 1.44 | -2.7 % | $ 5.26 B | USA |
 |
Seelos Therapeutics
SEEL
|
-40.5 M | - | -47.76 % | $ 6.27 M | USA |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |
 |
Atossa Therapeutics
ATOS
|
-37.1 M | $ 2.45 | -5.91 % | $ 21.1 M | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
-500 M | $ 16.09 | 2.78 % | $ 1.59 B | USA |
 |
Arcus Biosciences
RCUS
|
-376 M | $ 17.7 | -4.53 % | $ 1.9 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-14.6 M | $ 0.43 | 0.57 % | $ 5.3 B | Israel |
 |
Regeneron Pharmaceuticals
REGN
|
4.12 B | $ 808.08 | 0.38 % | $ 84.5 B | USA |
 |
Replimune Group
REPL
|
-317 M | $ 12.48 | 8.9 % | $ 1.16 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Rafael Holdings
RFL
|
-28.9 M | $ 1.18 | -9.92 % | $ 34.7 M | USA |
 |
REGENXBIO
RGNX
|
-146 M | $ 6.58 | -1.5 % | $ 339 M | USA |
 |
Kiromic BioPharma
KRBP
|
-21.5 M | - | 6.61 % | $ 3.08 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
128 M | $ 49.95 | 3.78 % | $ 898 M | USA |
 |
Compugen Ltd.
CGEN
|
31.8 M | $ 1.89 | -2.84 % | $ 177 M | Israel |
 |
Relay Therapeutics
RLAY
|
-299 M | $ 18.16 | -0.11 % | $ 3.12 B | USA |
 |
Coherus BioSciences
CHRS
|
-180 M | $ 1.0 | -0.5 % | $ 117 M | USA |
 |
Calithera Biosciences
CALA
|
-41.8 M | - | -10.95 % | $ 876 K | USA |
 |
Royalty Pharma plc
RPRX
|
1.56 B | $ 64.76 | 1.4 % | $ 27.8 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-192 M | $ 89.56 | 0.32 % | $ 5.82 B | USA |
|
Rezolute
RZLT
|
-82.9 M | $ 3.82 | -1.04 % | $ 397 M | USA |
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | USA |
 |
Aprea Therapeutics
APRE
|
-13.2 M | $ 0.43 | -16.94 % | $ 2.81 M | USA |
 |
Sana Biotechnology
SANA
|
-238 M | $ 2.36 | 1.29 % | $ 598 M | USA |
 |
Molecular Templates
MTEM
|
-3.82 M | - | -23.43 % | $ 495 K | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-31.5 M | $ 1.07 | -4.05 % | $ 49.6 M | USA |